,50,71 for the ENGAGE Consortium Using a genome-wide screen of 9.6 million genetic variants achieved through 1000 Genomes Project imputation in 62,166 samples, we identify association to lipid traits in 93 loci, including 79 previously identified loci with new lead SNPs and 10 new loci, 15 loci with a low-frequency lead SNP and 10 loci with a missense lead SNP, and 2 loci with an accumulation of rare variants. In six loci, SNPs with established function in lipid genetics (CELSR2, GCKR, LIPC and APOE) or candidate missense mutations with predicted damaging function (CD300LG and TM6SF2) explained the locus associations. The low-frequency variants increased the proportion of variance explained, particularly for low-density lipoprotein cholesterol and total cholesterol. Altogether, our results highlight the impact of low-frequency variants in complex traits and show that imputation offers a cost-effective alternative to resequencing.
Genome-wide association (GWA) studies have been successful in identifying genetic loci associated with complex diseases and traits. Owing to the design of genotyping arrays, most of the associated variants have been common in population samples. Although thousands of loci have been associated with complex diseases and traits, they so far typically explain only a fraction of the heritability 1 .
It has now become possible to search for associations with variants that are less frequent than in previous GWA studies, by analyzing large numbers of samples using whole-genome or whole-exome sequencing approaches. However, costs have so far limited the possibility for sequencing the tens of thousands of samples likely needed to detect significant associations for low-frequency variants.
Stochastic imputation to individuals genotyped using genotyping arrays in samples of sufficient size offers an alternative and cost-effective design to study the associations of low-frequency and rare variants at a genome-wide level. GWA studies of circulating lipids have been highly successful in identifying loci harboring common variants with small effects 2, 3 . In previous large-scale GWA studies, 157 loci have been shown to associate with lipid traits 2, 3 , but the strongest associations have almost exclusively been reported with common variants (minor allele frequency (MAF) > 5%) in European data sets, owing to the study designs.
In contrast, previously published variants known to cause mendelian forms of dyslipidemic syndromes and, more broadly, variants with known functional impact on lipids (FL SNPs) typically have low MAFs (≤5%). Although there are almost 40 loci where both FL SNPs and common SNPs implicated in GWA studies reside, it is often not known whether these associations are driven by the same underlying haplotypes and whether the mendelian variants explain the association in population samples.
A r t i c l e s
We sought to evaluate the impact of common (MAF > 5%), low-frequency (0.5% < MAF ≤ 5%) and rare (MAF ≤ 0.5%) genetic variants on circulating blood lipids in up to 62,166 European samples by imputing variants into the GWA study cohorts using the sequence-based 1000 Genomes Project reference panel 4 (Phase I interim release, June 2011). We aimed to determine (i) what the role of low-frequency variants and the burden of rare variants were in established lipid-associated loci; (ii) whether a dense set of markers from 1000 Genomes Project-based imputation could help to identify additional loci undetected in previous studies focused largely on common variants imputed to less dense reference panels from the HapMap Project; and (iii) how low-frequency and functional lipid variants contribute to the overall trait variance in comparison to common variants.
RESULTS

Study overview
To understand the contribution of low-frequency and rare genetic variation to circulating lipid concentrations, we undertook genome-wide imputation and association analysis in up to 62,166 individuals across 22 GWA study cohorts of European ancestry. Within each cohort, we performed sex-stratified inverse-rank normalization of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and total cholesterol (TC) measures, after adjustment of each trait for age, age 2 and study-specific covariates, including principal components to account for population structure. Case-control studies were further subdivided according to original data selection disease status. The GWA genotype scaffold for each cohort was imputed at up to ~37.4 million autosomal variants from the 1000 Genomes Project multi-ancestry reference panel 4 (Phase I interim release, June 2011). Across a subset of studies, ~98% and ~95% of variants present in the reference panel with 1% < MAF ≤ 5% and 0.5% < MAF ≤ 1%, respectively, were well imputed, as defined here by an IMPUTE 5, 6 info score of at least 0.4 (Supplementary Table 1) . However, as expected, imputation of rare variants (MAF ≤ 0.5%) proved more difficult, although ~65% of the rare variants polymorphic in the reference data set were well imputed across the same subset of studies.
Genome-wide screen for single-variant associations
We first tested for association of over 9.6 million genotyped or successfully imputed SNPs, enabled by the 1000 Genomes Project imputation, with circulating HDL-C, LDL-C, TG and TC levels. Overall, we detected 93 loci with genome-wide significant association (Supplementary Fig. 1 ) to one or more lipid traits (P < 5 × 10 −8 ), of which 10 loci have not been associated with lipids before (Table 1 and Supplementary Figs. 2 and 3) . Of the 83 previously established lipid loci, 79 had a new lead SNP for at least one lipid trait in our analysis (Supplementary Table 2 ). In 34 of the 79 loci, the linkage disequilibrium (LD; r 2 ) between the new lead SNP and the previously identified lead SNP was ≤40% (15 loci had r 2 ≤ 5%), and, in 56 loci, the newly identified variant was not present in the HapMap 2 imputation reference set used in previous studies. In 11 loci, the newly discovered lead SNP had MAF ≤ 5% and an average effect size of 0.18 (in s.d. units) in comparison to the average effect size of 0.05 for the previously established common lead SNP estimated in a cohort independent of the discovery scan to avoid bias due to winner's curse (n = 5,119; Fig. 1 ). These loci included the well-known lipid gene LPA for LDL-C (rs186696265: MAF = 0.8%, effect size = 0.26, P = 4.4 × 10 −14 , r 2 = 0.1%). In addition, we observed high-effect lead SNPs in PCSK9 for LDL-C (rs11591147: MAF = 1.9%, effect size = 0.53, P = 2.2 × 10 −92 , r 2 = 0.9%) and APOE for TC (rs7412: MAF = 7.1%, effect size = 0.41, P = 7.5 × 10 −239 , r 2 = 1.6%), which were already highlighted in the Global Lipids Genetics Consortium fine-mapping analyses 3 .
Using formal conditional analyses, in the MAFB locus, the new lowfrequency lead SNP with a large effect (effect size > 0.2, MAF ≤ 5%) explained the association of the previously identified lead SNP in 7 population cohorts (n = 12,834), although the LD between these variants was less than r 2 = 5% (Fig. 1) . Additionally, there were seven loci with two or more associated lead SNPs over 1 Mb apart that had r 2 < 5%, but in all cases the individual-level formal conditional analyses showed that the associations were completely explained by the known lipid-related SNPs in the regions (ZCCHC11, TMEM48 and PPAP2B associations explained by rs11591147 in the PCSK9 locus, olfactory receptor gene cluster association explained by rs7395581 in the LRP4-MADD locus, CCDC79 association explained by rs73591976 in the LCAT-RANBP10 locus, and PSG9 and IRF2BP1 associations explained by rs7412 in the APOE locus).
In 5 of the 79 loci, the lead SNP was a missense variant pointing to either a well-established causal gene (ANGPTL4, APOE, PCSK9 or CILP2) or to a new candidate gene (ABCA6). The APOE lead SNP for TC, rs7412 (p.Arg176Cys, MAF = 7.1%, r 2 = 0.7%), has been shown to associate with recessive familial type III hyperlipoproteinemia 7, 8 , and the PCSK9 lead SNP for LDL-C, rs11591147 (p.Arg46Leu, MAF = 1.9%, r 2 = 0.9%), has been shown to associate with extreme LDL-C values 9 . In the ANGPTL4 locus, the lead SNP in our GWA data npg was a predicted damaging missense variant, rs116843064 (p.Glu40Lys, MAF = 3.0%) with r 2 = 1.8% with the previously associated common lead SNP. The missense variant was associated with TG and HDL-C levels and has previously been associated with extreme TG values 10 . The CILP2 lead SNP, rs58542926 (in the TM6SF2 gene encoding a p.Glu167Lys substitution, MAF = 7.8%, r 2 = 98%), was associated with TC levels, risk of myocardial infarction and nonalcoholic fatty liver disease in two papers that appeared while this manuscript was in revision 11, 12 . Our new lead SNP in the ABCA6-ABCA8 locus, rs77542162 (in ABCA6 encoding a p.Cys1359Arg substitution, MAF = 2.0%, r 2 = 0.6%) associated with LDL-C and TC values (P = 1.6 × 10 −18 and 1.9 × 10 −13 , respectively).
In the genome-wide screening, we identified ten loci that have not previously been associated with lipids (near PROX1, CEP68, PRKAG3, ADAMTS3, MTHFD2L, GPR85, RMI2, TM4SF5, GATA6 and ZNF274), with four having a low-frequency variant (MAF < 5%) as the lead SNP (lowest MAF = 0.7%, rs182616603 in the MTHFD2L locus; Table 1 ). All except one of the lead SNPs had not been surveyed in the previous GWA studies based on HapMap 2 imputation. The one lead SNP that was present in the HapMap 2 imputation reference panels was in the 5′ UTR of PROX1 (rs340839, associated with TG, P = 4.4 × 10 −12 ) and was correlated with a marker previously associated with fasting glucose levels and type 2 diabetes 13 (rs340874, r 2 = 74.7%). The lead SNP in the HDL-C-associated PRKAG3 locus was located upstream of the gene, close to a transcription factor binding site. PRKAG3 is a regulatory subunit of the AMP-activated protein kinase (AMPK), which has previously been shown to regulate lipid homeostasis 14 .
The role of FL SNPs in the general population
In eight loci (PCSK9, CELSR2-SORT1, GCKR, the human leukocyte antigen (HLA) region, LPL, LIPC, CETP and APOE), we tested whether the variants known to cause mendelian forms of dyslipidemic syndromes and, more broadly, with known functional impact on lipids also explained the associations of the common lipid SNPs. These FL SNPs were identified by searching the Online Mendelian Inheritance in Man (OMIM) database and confirmed through analysis of the literature, and SNPs previously reported to affect gene transcription or translation in cellular and/or animal models were taken forward into conditional analyses in 7 population cohorts (n = 12,834; Supplementary Fig. 4 and Supplementary Tables 3 and 4) .
The FL SNPs explained the lead SNP association (with P < 5 × 10 −8 and conditional P > 0.01 for the lead SNP) in four of the eight loci (CELSR2-SORT1, GCKR, APOE and LIPC; Table 2 and Supplementary Fig. 5 ). In the GCKR and APOE loci, the lead SNPs of our GWA screen were FL SNPs (rs1260326 (p.Pro446Leu) 15 and rs7412 (p.Arg158Cys) 7, 8 for GCKR and APOE, respectively).
In the GCKR locus, rs1260326 explained the population-level association. Similarly, in the APOE locus, the two FL SNPs rs7412 and rs429358 (p.Cys112Arg) 16 defining the APOE ε2, ε3 and ε4 isoforms 17 explained the association (Supplementary Fig. 5d,e) . The LIPC association was explained by rs1800588 (−514C/T, MAF = 25.1%) 18 and rs113298164 (p.Thr383Met, MAF = 1.4%) 19 for TC and TG ( Supplementary Fig. 5f,g ) but not for HDL-C ( Supplementary  Fig. 5h ). All results for the conditional analyses are presented in Supplementary Table 5 .
Search for new functional candidate SNPs
We then searched for potential candidate causal SNPs in the lipidassociated loci (157 established and 10 newly discovered) with a similar predicted function to well-characterized FL SNPs. We identified possible functional variants in four loci without known functional variants at the time of analysis (MLXIPL, LRP4-MADD, SOST-DUSP3 and CILP2) and tested whether the identified variants explained the significant association seen in the locus (Supplementary Table 6 ). The results of the conditional regression analyses for these four loci are presented in Supplementary Figure 6 and Supplementary Table 7.
In the SOST-DUSP3 and CILP2 loci, the candidate functional variants explained the genome-wide associations of the lead SNPs in the region in the test set (in both loci, conditional P > 0.01). In the SOST-DUSP3 locus (Fig. 2a) , a single low-frequency, deleterious missense variant, rs72836561 (p.Arg82Cys, MAF = 2.7%, P = 1.36 × 10 −8 , effect size = 0.23) in the CD300LG gene, explained the whole regional association, implicating CD300LG as a likely candidate gene in the locus for TG levels. The same variant has also recently been shown to associate with HDL-C and with fasting serum triacylglycerol levels in exomewide association studies 20, 21 . Figure 1 Change in P value after analysis conditional on the new lead SNP and comparison of new and previously reported lead SNP effect sizes and allele frequencies per locus. In both plots, each arrow represents one locus and trait where significant association was found in our screening and in one of the previously published large-scale screening studies 2, 3 ; color is based on the LD between the known and new lead SNPs. (a) On the y axis are the −log 10 (P values); arrows start from the P value seen in the unconditional analysis in the Finnish subset (n = 12,834) and point to the P value in analysis conditional on the new lead SNP. (b) Each arrow starts from the effect and MAF for the established lead SNP and points to the corresponding values for the new lead SNP. Red asterisks represent the new low-frequency lead SNPs. Effects have been estimated in the FRCoreExome9702 sample set (n = 5,119), which is independent of the discovery set. For clarity, only results for loci with r 2 < 0.4 have been presented. 
A r t i c l e s
In the CILP2 locus for LDL-C, TC and TG, two independent missense variants (r 2 = 0) in the TM6SF2 gene-a deleterious missense variant, rs187429064 (MAF = 3.6%, p.Leu156Pro; for TC, effect size = −0.25 and P = 2.03 × 10 −11 ), and a probably damaging missense variant, rs58542926 (MAF = 6.3%, p.Glu167Lys; for TC, effect size = −0.18 and P = 6.47 × 10 −12 )-explained the lead SNP association for LDL-C, TC and TG (Fig. 2b, Supplementary Fig. 7 and Supplementary Table 7 illustrate the result of the conditional analysis for TC).
Biological profiling of the CD300LG and TM6SF2 genes CD300LG (CD300 molecule-like family member G; also called nepmucin) is a type I cell surface glycoprotein that contains a single immunoglobulin V-like domain 22 and has a role in lymphocyte binding and transmigration 23 . The predicted damaging mutation (encoding p.Arg82Cys) in our TG-and HDL-C-associated locus, rs72836561, affects the immunoglobulin domain of CD300LG, which binds to lymphocytes. CD300LG is expressed in the vascular endothelial cells of various tissues and is located both at the plasma membrane and in intracellular vesicles 23, 24 . Although CD300 family members have been demonstrated to bind lipids 25 , the function of CD300LG in lipid metabolism has not been studied. TM6SF2 (transmembrane 6 superfamily member 2) 26 is a multi-pass membrane protein, in which the predicted deleterious missense mutation (rs1874290064; encoding p.Leu156Pro) maps to the predicted fifth transmembrane domain and the probably damaging missense mutation (rs58542926; encoding p.Glu167Lys) maps to the exposed non-transmembrane domain. TM6SF2 has been shown to localize to the endoplasmic reticulum (ER) compartment/ER-Golgi intermediate compartment (ERGIC) and to influence TG secretion in liver cells 27 . Additionally, the p.Glu167Lys missense substitution was shown to alter serum lipid profiles in humans, and knockdown of Tm6sf2 in mice was shown to lead to increased liver TG content and decreased very-low-density lipoprotein (VLDL) secretion 11, 12 .
We further characterized these two genes by using the Gene Network database 28 (see the Online Methods for details) for tissuespecific expression, pathway analysis and prediction of mouse knockout phenotype, based on the Mouse Genome Informatics (MGI) database 29 . We found that CD300LG is coexpressed with genes whose knockout increases circulating VLDL particle levels in mice (prediction P = 1.4 × 10 −9 ), in line with our phenotype of higher TG levels in humans carrying the deleterious missense variant of CD300LG. For TM6SF2, the MGI-based predictions, using coexpression of genes, included abnormal lipid levels (decreased LDL-C, prediction P = 8.6 × 10 −19 ; decreased VLDL, prediction P = 2.5 × 10 −29 ; decreased TC, prediction P = 6.3 × 10 −24 ) among the most highly significant predictions, in line with recent publications and our association results. All associated MGI-based knockout predictions (P < 1 × 10 −6 ) are shown in Supplementary Table 8 , and lists of genes with the same and stronger MGI-based predictions can be found in Supplementary Table 9 .
Both genes were found to be among the most highly expressed genes in tissues important for lipid absorption and/or metabolism on the basis of the analysis using the Gene Network database (Supplementary Table 10 ). CD300LG is highly expressed in muscles, plasma and adipose tissue, and TM6SF2 is highly expressed in liver, plasma and intestines. Furthermore, on the basis of the gene expression network analysis, TM6SF2 likely interacts with proteins involved in intestinal absorption (Supplementary Table 11 ), and it is most highly predicted to function as a lipid transporter (P = 1.05 × 10 −14 , prediction is based on coexpressed genes; Supplementary Table 12 ).
Contribution of low-frequency variants to lipid variation
We estimated the proportion of the variance in lipid traits explained by variants in the 157 previously established and 10 newly identified loci in an additional cohort of 5,119 individuals from the Finrisk cohort (FRCoreExome9702) not included in our discovery metaanalysis. The lead SNPs from all three GWA screens (Teslovich et al. 2 , Willer et al. 3 and this study), together with the FL SNPs and new candidate functional SNPs, were divided into two groups on the basis of their allele frequency in the FRCoreExome9702 data set. Common SNPs explained 8.2% (TG), 11.9% (HDL-C), 
16.3% (LDL-C) and 16.2% (TC) of the variance in lipid levels (Fig. 3) . Together with the low-frequency variants, we now explain 9.3%, 12.8%, 19.5% and 18.8% of the variance in TG, HDL-C, LDL-C and TC concentrations, respectively. We also evaluated the contribution of our SNPs to the additive genetic variance estimated by a linear mixed model (LMM) applied to 10,472 individuals from 6 Finnish GWA cohorts (Online Methods) and to narrow-sense heritability estimates obtained from a large twin study 30 . The narrow-sense heritability estimates from the twin study were 40%, 51%, 51% and 33%, and the LMM estimates derived from the Finnish subset were 26%, 29%, 27% and 19% (for HDL-C, LDL-C, TC and TG, respectively; see the Online Methods for details). We estimate that the SNP set explained at least 28.1%, 32.0%, 38.2% and 36.7% (narrow-sense heritability) and at most 48.9%, 49.2%, 67.2% and 69.6% (LMM heritability estimate) of the additive genetic variance in TG, HDL-C, LDL-C and TC concentrations, respectively.
Gene-based association analysis
To complement the single-variant tests for low-frequency variation, we used GRANVIL 31 to test for the association of ARMC6   SUGP2  HOMER3  DDX49  COPE  GDF1  CERS1  UPF1   NCAN  NR2C2AP  RFXANK  MEF2BNB  MEF2BNB-MEF2B  MEF2B  TMEM161A  SLC25A42   YJEFN3  NDUFA13  TSSK6  GATAD2A  MAU2  SUGP1  TM6SF2  HAPLN4   ZNF506  ZNF14  ZNF101  ATP13A1  GMIP  LPAR2  PBX4  CILP2   ZNF486  ZNF90  ZNF682  ZNF93  ZNF253 npg A r t i c l e s each lipid trait with accumulations of minor alleles ('mutational load') at well-imputed rare variants within genes in a subset of 30,463 individuals from 15 cohorts (Online Methods and Supplementary Table 1) .
We observed genome-wide significant evidence of association (P < 1.7 × 10 −6 , Bonferroni correction for 30,000 genes) of HDL-C with the mutational load of rare nonsynonymous variants in LIPC (P = 2.1 × 10 −7 , mean MAF = 0.26%; Supplementary Fig. 8 ). To further investigate the relationship between gene-based and single-SNP association signals at this locus, we performed conditional analysis, adjusting the effect of the mutational load for the lead SNP in our study (rs261291). The association of HDL-C with rare nonsynonymous variants in LIPC remained relatively unchanged (conditional P = 3.6 × 10 −6 ), suggesting that the mutational load of the gene is independent of the GWA signal at this locus.
We identified two genes for which the mutational load of rare variants (irrespective of annotation) was associated with TG concentration at genome-wide significance, both mapping to the APO gene cluster: ZPR1 (P = 1.5 × 10 −11 , mean MAF = 0.25%) and APOA5 (P = 5.0 × 10 −8 , mean MAF = 0.24%). Conditional analyses, adjusting for the lead SNP (rs964184) for the association at the APO gene cluster, reduced the strength of the association of rare variants in both ZPR1 and APOA5 with TG concentration but could not fully explain the effect of the mutational load of these genes (Supplementary Table 13 ). As ZPR1 and APOA5 map within 2 kb of each other, we further investigated the impact of LD on the association signal in the region with conditional analyses adjusting the association for the mutational load of each gene by that at the other gene (Online Methods). The strength of association of both genes was reduced but not fully attenuated after adjusting for the effect of the other gene (ZPR1 conditional P = 1.4 × 10 −5 ; APOA5 conditional P = 6.3 × 10 −4 ), suggesting that the effects of rare variants in these two genes are only partially correlated with each other.
DISCUSSION
Using 1000 Genomes Project-imputed data with a dense SNP set, we were able to impute 9.6 million common and low-frequency SNPs with good quality in 62,166 European samples. With GWA meta-analysis on these data, we identified 10 new loci associated with blood lipid traits and new lead SNPs in 79 previously known lipid-related loci. In 11 previously known loci, the new lead SNP had MAF ≤5%, and, on average, the newly identified low-frequency variants showed an effect size that was 3.6 times greater than that of the corresponding lead SNP in previous meta-analysis studies. Moreover, in four of the ten newly discovered loci, the lead SNPs were low-frequency variants.
Our association results show that low-frequency variants have a much larger contribution to lipid variation in the general population than has previously been shown 2, 3 . In several cases, associations that had previously been tagged by common variants are now led by variants with an allele frequency of 0.5−5% and larger effect sizes. The large effect sizes also show in the population variance in lipid traits explained, where low-frequency variants add 3.2% to the variance explained for LDL-C when added to the common variants identified in previous reports or in our study, even though there are relatively few carriers of low-frequency variants in the general population.
Although GWA studies have typically identified associations with lipid levels in cohorts with normal population variation, known functional variants-some causing mendelian forms of lipid syndromes and others changing protein structure or disturbing gene transcription-have often been identified in patients and families with extreme lipid values. We found four regions where the population-level association was explained by known mendelian and/or functional SNPs, suggesting that the effects of FL SNPs may generalize to European samples with normal lipid variation. Taken together, the successfully imputed and tested functional SNPs, in combination with the new functional candidate variants, explained 2.2−6.7% of the variation in lipid traits at the population level.
As the FL SNPs explained the population-level association through LD structure in four of the eight loci, we reversed this connection to identify potential candidate genes by finding SNPs with a similar functional profile to the FL SNPs in lipid-associated loci with no previous strong functional candidates. Using this strategy, we identified two loci where missense variants with predicted damaging or deleterious consequences explained the lead SNP associations from the GWA meta-analysis, thus, together with previous evidence, supporting the role of CD300LG (TG) and TM6SF2 (TC, LDL-C and TG) in lipid metabolism, as evidenced by gene network analysis, gene expression correlations, predicted functions in mice and expression patterns across organs, with each type of data suggesting potential links to lipid metabolism. TM6SF2 was recently listed among genes potentially affecting LDL-C uptake in a small interfering RNA (siRNA) screen focused on cellular lipid phenotypes within previously published blood lipid-associated GWA loci 32 . Additionally, two reports showing strong evidence of a role for one of the two TM6SF2 missense variants, encoding p.Glu167Lys, on VLDL and TG metabolism were recently published 11, 12 . In our data, this variant does not by itself explain the whole regional association; however, the association was explained when this variant was considered together with a second missense variant with lower MAF and larger effect. Overall, our results reinforce the importance of CD300LG and TM6SF2 for blood lipid levels in the general population. 
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A r t i c l e s
In two established GWA study loci with common lead SNPs, our analyses showed associations of the mutational load of rare variants with lipid traits. The association of HDL-C with rare variants in LIPC has previously been reported 33 , and we also demonstrate that this signal is independent of the common lead GWA study SNP at this locus. We identified significant association with TG concentration for the accumulation of rare variants in APOA5, but conditional analysis on the GWA lead SNP suggested that the single-variant and genebased associations are partially correlated. However, the GWA lead SNP alone was not sufficient to fully explain the gene-based signal. An excess of minor alleles in APOA5 has previously been associated with hypertriglyceridemia 34 , but we report here an impact of this gene on TG concentrations at a population level. Although imputation enables recovery of ~65% of rare variants that are present in the 1000 Genomes Project haplotypes, many will not be represented in the reference panel. Resequencing in large sample sizes will be required to fully elucidate the role of rare variation at these GWA loci on HDL-C and TG levels and to inform functional studies to determine the underlying mechanisms through which these genes influence the regulation of lipids.
In addition to the 93 loci identified, there were 7 loci showing 2 or more association signals that were more than 1 Mb from each other and where the LD between the lead SNPs was small (r 2 ≤ 0.05). However, in formal conditional analyses of these loci using individuallevel data, the most strongly associated SNPs in the locus also explained the other associations, even over a physical distance of 1 Mb or more or a low level of LD. As these observations were only seen after careful conditional testing of individual-level data, they also highlight how challenging it is to interpret association patterns using only summary-level results on single-SNP analyses.
There are some potential limitations to our genetic study. Although we used a dense sequence-based global imputation panel, this panel does not cover all low-frequency and rare variants in Europeans. Similarly, although the imputation reference set included a large number of low-frequency SNPs and other variants with known functional impact on lipids, some were either missing from the panel or not polymorphic in our test sets of seven Finnish cohorts. Therefore, we are likely missing some additional effects in our data. As more individuals are sequenced and the resulting data are made available as imputation reference panels, more variants can also be imputed with high confidence and tested for associations.
In conclusion, our study shows that low-frequency variants contribute substantially to population variance in lipid levels. The variants known to cause mendelian forms of lipid syndromes and variants with known functional effects on lipid levels explain the common variant association in overlapping loci, establishing a similar role for these variants in patient series with extreme phenotypes and in general populations. In addition, we found ten new lipid-associated loci for further investigation, and, for two previously known lipid loci, we identified new candidate missense variants with predicted damaging function. When combining all the accumulated genetic evidence, we could explain up to 19.5% of the variation in lipid traits. By considering the aggregate effects of rare variants within genes, we identified three transcripts associated with lipids in already established GWA loci that could not be fully explained by the common lead SNPs reported in this study. Together, these observations show the important role of low-frequency functional SNPs in variation in lipid levels in the general population and represent new therapeutic opportunities for treating dyslipidemias and preventing cardiovascular diseases. They also highlight the idea that imputation is a cost-effective approach for assessing association with low-frequency and rare variants without the need for costly resequencing experiments.
URLs. Online Mendelian Inheritance in Man (OMIM) database, http://www.omim.org/; Gene Network database, http://genenetwork. nl/genenetwork/; Mouse Genome Informatics (MGI) database, http://www.informatics.jax.org/; 1000 Genomes Project, http:// www.1000genomes.org/; SNPTEST software, http://mathgen.stats. ox.ac.uk/genetics_software/snptest/snptest.html; R: a language and environment for statistical computing, http://r-project.org/.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Genotype quality control and imputation. Before imputation, all cohorts (see the Supplementary Note for cohort information) went through a quality control pipeline with the following criteria: samples with genotype call rate <95%, sex discrepancies, excess heterozygosity or cryptic relatedness were removed. Additionally, ancestry outliers and multidimensional scaling (MDS) outliers were excluded. SNPs with MAF <1%, with call rate <95% (or <99% if the SNP had MAF <5%) or that failed the Hardy-Weinberg equilibrium exact test (precise threshold depending on study) and sex-chromosome SNPs were removed. Genotyping platforms, study-specific quality control criteria and other details are presented in Supplementary Table 14 . Imputation for the data sets was performed using IMPUTE (v2.0) 5, 6 (unless stated otherwise) with the 1000 Genomes Project June 2011 imputation reference panel with 2,188 haplotypes 4 .
Phenotype measures. All four lipid traits (HDL-C, LDL-C, TC and TG) were measured using basic enzymatic methods. Summary statistics of phenotypes in each cohort are presented in Supplementary Table 15 . Individuals on lipidlowering medication were excluded, and measures deviating by more than 5 s.d. were set to missing. All four phenotypes were adjusted for age, age 2 and the first three genetic principal components. Principal components were derived from the GWA data using principal-component analysis of the identity-by-state (IBS) sharing matrix for each study separately 35 . Both the removal of outliers and the adjustments were performed for males and females separately in each of the studies for all four traits. The residuals resulting from the adjustments were then inverse-normal transformed to the N(0, 1) distribution. The GenMets and DGI cohorts were additionally stratified by metabolic syndrome and type 2 diabetes case status, respectively. Only men were available in the GerMIFS I and II and ULSAM cohorts. As the NTR cohort has related samples, males and females were analyzed together to account for relatedness.
Single-variant association and meta-analysis methods.
A GWA analysis was run in each of the cohorts separately (see Supplementary Table 14 for software details). Quality control on the association results was performed centrally to have as harmonized a data set as possible. In this procedure, the following SNPs were removed: SNPs with minor allele count <3; SNPs with imputation quality Proper_INFO <0.4; duplicates; and genotyped SNPs with Hardy-Weinberg equilibrium P < 1 × 10 −4 . The meta-analysis was run using the GWAMA software tool 36, 37 , which uses fixed-effects inverse variance-weighted meta-analysis. Genomic control was applied to each of the cohorts in the meta-analysis. SNPs with <50% of the cohorts contributing or SNPs showing between-study heterogeneity of effect size (Cochran's Q test statistics I 2 < 50%) were discarded from the meta-analysis results. After these quality control steps, the maximum number of SNPs in the analysis was 9,657,952.
SNP associations with P < 5 × 10 −8 were considered genome-wide significant, and lead SNPs were required to be at least 1 Mb away from adjacent lead SNPs. In areas with long-range LD, formal conditional analysis was performed in a subset of 12,834 Finnish samples to ensure the independence of the lead SNPs.
Search for known functional lipid SNPs. We searched the OMIM database for information on 167 loci that had been found to associate with one of the studied traits (HDL-C, LDL-C, TC and TG) in either of the 2 previously published GWA studies 2,3 or in our genome-wide screen. For each of these 167 loci, every gene in a 2-Mb region centered on the published lead variant was looked up in the OMIM database, and the variants associated with lipid-related syndromes or population-extreme lipid values were collected. Of the 167 loci, 38 had OMIM-listed lipid-related SNP variants within the searched window. As our genotype data only included SNP variants, we could not study deletions, insertions and other copy number variations. Each of the OMIM-listed lipid-related SNPs was subsequently mapped to genome build 37 using the dbSNP database for rsID identification. Of the 38 loci, 18 had at least one polymorphic OMIM-listed SNP in the imputed Finnish test set of 7 cohorts (Corogene controls, FTC, GenMets, HBCS, NFBC1966, YFS and PredictCVD; combined n = 12,834). To be sure of the functionality of these SNPs, additional literature searching was performed to find evidence of effects on gene transcription or translation. Of the 18 loci, 8 showed genome-wide significant association in the Finnish meta-analysis and had at least one variant with evidence of functional impact on lipid levels in cell or animal models.
Formal conditional association analysis in loci containing known functional lipid SNPs. Formal conditional analyses were run using the Finnish test set of 7 cohorts (n = 12,834). Each of the cohorts was analyzed separately with linear regression analysis implemented by SNPTEST software. In each cohort, the imputation quality threshold of Proper_INFO > 0.4 was applied. Each locus was analyzed only for the trait(s) for which it had previously been reported in already published GWA studies. In conditional analysis on SNP(s), the phenotype was first adjusted with the SNP(s), and a linear regression model was then fitted for the remaining residuals. When we performed iterative conditional analyses at a locus, the signal was first conditioned on the most significant variant and then conditioned on the top variant from the initial conditional analysis and so forth. Loci where the initial lead SNP association in the conditional analyses had conditional P < 0.01 and no further significant associations (conditional P < 5 × 10 −8 ) were found within the 2-Mb window were considered to be explained.
The results from the seven Finnish cohorts were combined using GWAMA. Because the conditional analyses were run only for the preselected 2-Mb windows, genomic inflation factor (λ) correction could not be applied. However, we did not see substantial inflation in the GWA analysis of all four traits in the seven Finnish cohorts (λ ranged from 0.992.991.029, depending on the trait and cohort).
Search for functional candidate SNPs. To explore suggestive functional variants causing association signals at loci that do not have lipid-related OMIMlisted variants, we selected nine loci: GALNT2, MLXIPL, PPP1R3B, TRIB1, ADAMTS3, LRP4-MADD, SOST-DUSP3, CILP2 and HNF4A. These loci had been significantly associated with lipid traits in either previously published GWA studies 2,3 or in our genome-wide screen, as well as in the meta-analysis using 7 Finnish cohorts (n = 12,834). In each of these loci, 2-Mb windows were searched for functional variants that had association P < 5 × 10 −4 . Candidate SNPs were annotated using the Ensembl database, and functional effects were predicted using the Provean 38 , SIFT 39 and PolyPhen 40 databases. If a variant was annotated as a missense mutation predicted to be damaging in at least one of the prediction databases, it was treated as an FL SNP, and formal conditional analysis was performed to investigate whether it explained the association.
Gene network analysis. We used 2,206 principal components that had been derived from a data set of 77,840 samples using Affymetrix microarrays (54,736 human, 17,081 mouse and 6,023 rat). Because gene set enrichment analysis showed that each of these components was enriched for at least one biological pathway, we used these components to develop a gene function prediction algorithm. To do so, we first determined whether each of the components was enriched for a given gene set by performing a t test (contrasting genes known to be part of this pathway with all other genes) and transformed the T statistics into z scores. Subsequently, we calculated the eigenvector coefficients of the 2,206 components for individual genes of interest with the z-score profile of this gene set to predict the gene's involvement in a specific pathway (details provided in Fehrmann et al. 28 ; see Cvejic et al. 41 and Wood et al. 29 for a short description). We used a permutation strategy to determine the significance of the predictions, controlling the false discovery rate at 5%. On the basis of the MGI mouse knockout database, we predicted that CD300LG would increase circulating VLDL-C levels. For TM6SF2, the most significantly predicted biological process was intestinal absorption. Only highly significant predictions (permuted P < 1 × 10 −6 ) were taken into account when profiling the two genes.
We text-mined the sample descriptions provided by experimenters who uploaded microarray data to the Gene Expression Omnibus (GEO). This textmining allowed us to determine the tissue or cell type for the majority of the samples. We subsequently used Wilcoxon-Mann-Whitney tests in the human samples from the Affymetrix U133 Plus 2.0 platform to ascertain how highly each gene was expressed in samples of a certain tissue or cell type as compared to samples in other tissues and cell types. We found that CD300LG was highly expressed in adipose tissue, heart, muscle and plasma and that TM6SF2 was highly expressed in ileum and intestinal mucosa.
